# OnCo record paper-northcott-next-personal-validation-oncotarget-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-northcott-next-personal-validation-oncotarget-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-northcott-next-personal-validation-oncotarget-2024" ;
  schema:name "Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay"@en ;
  schema:description "The laboratory validation of Personalis' whole-genome blood test for leftover cancer, which detected tumour DNA at a few parts per million."@en ;
  schema:url <https://onco.cc/key-papers/paper-northcott-next-personal-validation-oncotarget-2024/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.18632/oncotarget.28565>, <https://pubmed.ncbi.nlm.nih.gov/38484152/> ;
  schema:sameAs <https://doi.org/10.18632/oncotarget.28565> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Northcott J, Bartha G, Harris J, et al." ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:drugs <https://onco.cc/drugs/next-personal/> ;
  onco:companies <https://onco.cc/companies/personalis/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/> ;
  onco:journals <https://onco.cc/journals/oncotarget/> .